RVPH vs RZLT

Reviva Pharmaceuticals Holdings vs Rezolute, Inc. — Valuation Comparison 2026

RVPH

Biotechnology
Reviva Pharmaceuticals Holdings
Quality
3.7
out of 10
Value Trap
24
SAFE
Price
$0.43
Last close
Models
5/13
Active
VS

RZLT

Biotechnology
Rezolute, Inc.
Quality
4.0
out of 10
Value Trap
30
LOW
Price
$3.27
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType RVPH Fair ValueRVPH Upside RZLT Fair ValueRZLT Upside
Bayesian DCF Intrinsic $1.03 +142.9% $0.94 -71.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.03 -96.6% $0.63 -80.7%
Dynamic NAV Asset-Based $1.46 -55.2%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for RVPH vs RZLT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RVPH vs RZLT — Which Stock Is More Undervalued?

RZLT scores higher with a 4.0/10 quality rating vs RVPH's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Reviva Pharmaceuticals Holdings (RVPH) and Rezolute, Inc. (RZLT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RVPH currently trades at $0.43 with a QOC of 3.7/10, while RZLT trades at $3.27 with a QOC of 4.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).